We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$267M
1-Year Est. Return
48.26%
This Fund
S&P 500
This Quarter
Est. Return
-13.78%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$35.9M
AUM Growth
-$38M
(-51%)
Cap. Flow
-$28.8M
Cap. Flow
% of AUM
-80.21%
Top 10 Holdings %
Top 10 Hldgs %
65.11%
Holding
23
New
2
Increased
10
Reduced
8
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$1.73M |
| 2 |
Televisa
TV
|
+$1.49M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$724K |
| 4 |
Antero Resources
AR
|
+$546K |
| 5 |
Kinder Morgan
KMI
|
+$291K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$27.3M |
| 2 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$1.69M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$1.49M |
| 4 |
QVCGA
QVC Group Inc Series A
QVCGA
|
+$1.47M |
| 5 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$1.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.68% |
| 2 | Financials | 8.11% |
| 3 | Consumer Discretionary | 7.73% |
| 4 | Communication Services | 7.19% |
| 5 | Energy | 6.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vanguard FTSE Emerging Markets ETF
VWO
$119B
| $10.2M | 28.37% |
307,890
-750,891
| -71% | -$27.3M |
|
2
Viasat
VSAT
$9.76B
| $1.63M | 4.53% |
25,305
+1,231
| +5% | +$75.1K |
|
3
Incyte
INCY
$23.4B
| $1.58M | 4.39% |
14,287
+257
| +2% | +$28.8K |
|
4
Arch Capital
ACGL
$35.4B
| $1.51M | 4.21% |
61,653
-9,096
| -13% | -$213K |
|
|
5
BioCryst Pharmaceuticals
BCRX
$2.36B
| $1.48M | 4.11% |
+129,415
| New | +$1.73M |
|
|
LVNTA
6
DELISTED
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
| $1.47M | 4.09% |
36,425
+1,560
| +4% | +$63.1K |
|
7
LPL Financial
LPLA
$26B
| $1.4M | 3.9% |
35,231
-964
| -3% | -$41.5K |
|
|
ESRX
8
DELISTED
Express Scripts Holding Company
ESRX
| $1.38M | 3.85% |
17,064
-48
| -0.3% | -$4.18K |
|
9
Liberty Media Series C
FWONK
$25.6B
| $1.37M | 3.83% |
56,344
+175
| +0.3% | +$4.49K |
|
10
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.37M | 3.82% |
41,505
+2,094
| +5% | +$87.1K |
|
|
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.33M | 3.7% |
34,504
-3,113
| -8% | -$140K |
|
|
ANAC
12
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $1.31M | 3.64% |
11,096
-12,957
| -54% | -$1.69M |
|
|
WBC
13
DELISTED
WABCO HOLDINGS INC.
WBC
| $1.3M | 3.63% |
12,439
+821
| +7% | +$96.1K |
|
|
GHDX
14
DELISTED
Genomic Health, Inc.
GHDX
| $1.29M | 3.58% |
60,828
+5,862
| +11% | +$151K |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.27M | 3.53% |
8,101
-1,178
| -13% | -$215K |
|
|
NVTA
16
DELISTED
Invitae Corporation
NVTA
| $1.25M | 3.49% |
173,743
+68,882
| +66% | +$724K |
|
|
17
Kinder Morgan
KMI
$71.9B
| $1.22M | 3.4% |
44,064
+8,791
| +25% | +$291K |
|
|
18
Televisa
TV
$1.43B
| $1.21M | 3.36% |
+46,388
| New | +$1.49M |
|
|
19
Antero Resources
AR
$10.4B
| $1.18M | 3.28% |
55,717
+20,514
| +58% | +$546K |
|
20
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.18M | 3.27% |
11,155
-1,012
| -8% | -$135K |
|
|
QVCGA
21
DELISTED
QVC Group Inc Series A
QVCGA
| – | – |
-1,090
| Closed | -$1.47M |
|
|
ONCE
22
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| – | – |
-23,333
| Closed | -$1.41M |
|
|
DYAX
23
DELISTED
DYAX CORPORATION
DYAX
| – | – |
-56,383
| Closed | -$1.49M |
|
Similar funds
CFG
PC
ALC
TWM
IP
SP
EAIC
STB
Emory University's Q3 2015 Portfolio in Review
As of Q3 2015, Emory University held 23 positions worth $35.9M, down 51% from $73.9M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Emory University withdrew a net $28.8M in Q3 2015, closing 3 positions and reducing 8 holdings. Its most notable exit was DYAX CORPORATION, an estimated $1.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 13% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Emory University opened a new position in BioCryst Pharmaceuticals worth $1.48M.
- Emory University's largest Q3 2015 buy was BioCryst Pharmaceuticals: 129,415 shares worth $1.48M.
- Emory University added most to Invitae Corporation in Q3 2015, an estimated $724K increase.
- Emory University's biggest Q3 2015 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $27.3M.
- Emory University fully exited DYAX CORPORATION in Q3 2015, selling an estimated $1.49M.
- Emory University's ten largest holdings make up 65% of its $35.9M portfolio in Q3 2015.
- Emory University opened 2 new positions and closed 3 in Q3 2015.
- Emory University's portfolio value fell 51% quarter-over-quarter to $35.9M.
Based on Emory University's 13F filing for Q3 2015, filed 16 Nov 2015.